Advertisement
Research Article

Immunopotentiation of Trivalent Influenza Vaccine When Given with VAX102, a Recombinant Influenza M2e Vaccine Fused to the TLR5 Ligand Flagellin

  • H. Keipp Talbot mail,

    keipp.talbot@vanderbilt.edu

    Affiliation: Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America

    X
  • Michael T. Rock,

    Affiliation: Division of Infectious Diseases, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America

    X
  • Casey Johnson,

    Affiliation: Johnson County Clin-Trials, Lenexa, Kansas, United States of America

    X
  • Lynda Tussey,

    Affiliation: VaxInnate Corporation, Cranbury, New Jersey, United States of America

    X
  • Uma Kavita,

    Affiliation: VaxInnate Corporation, Cranbury, New Jersey, United States of America

    X
  • Anita Shanker,

    Affiliation: Health Decisions, Durham, North Carolina, United States of America

    X
  • Alan R. Shaw,

    Affiliation: VaxInnate Corporation, Cranbury, New Jersey, United States of America

    X
  • David N. Taylor

    Affiliation: VaxInnate Corporation, Cranbury, New Jersey, United States of America

    X
  • Published: December 28, 2010
  • DOI: 10.1371/journal.pone.0014442

Viewed info

Cited info

Saved info

Discussed info

Questions or concerns about usage data? Please let us know.